To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

May 08, 2018

Today's Rundown

Featured Story

Ascletis files for Hong Kong IPO as floodgates open to prerevenue biotechs

Ascletis Pharma has become the first company to seek to list in Hong Kong under the exchange’s new, more relaxed rules on biotech IPOs. The antiviral disease specialist will use the cash to win approvals for hepatitis C drugs licensed from Roche and Presidio Pharmaceuticals.

Top Stories

Merck and OncoSec expand Keytruda/IL-12 collaboration into triple-negative breast cancer

Merck and OncoSec Medical are partnering up on a second clinical trial, this time combining two of their immunotherapies in metastatic triple-negative breast cancer, following a similar collaboration in melanoma announced just one year ago.

With patisiran FDA nod imminent, Alnylam preps CNS pipeline for the clinic

On the back of promising preclinical data, Alnylam is gearing up to move RNAi therapies for central nervous system disorders into the clinic.

[Sponsored] Optimize Human Gene Transfer Trials: Create Efficiencies with Coordinated IRB & IBC Review

Avoid delays in gene transfer trial start-up with tips from leading IRB and IBC experts.

Faron Pharma flummoxed as Traumakine fails in ARDS

Shares in Finnish biotech Faron Pharma are in free fall this morning after a late-stage trial of its lead drug Traumakine for acute respiratory distress syndrome (ARDS) comprehensively failed.

Autolus seeks $100M IPO to take next-gen CAR-Ts deep into the clinic

Autolus has filed to raise $100 million in a Nasdaq IPO. The British biotech wants the cash to bankroll clinical trials of a clutch of next-generation CAR-Ts designed to broaden the use of cell therapies while improving their safety and efficacy.

Resources

[Whitepaper] Compliance Certificate and Training for Life Sciences Professionals

4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics.

[Whitepaper] 2018 Life Sciences Trends

What are the biggest trends in life sciences this year?

[Whitepaper] Choosing the Best Steriles Dosage Form for Your Phase I Clinical Supply Needs

There are many parenteral dosage forms from which the pharmaceutical scientist can choose to develop their drug product. In this article, the author discusses the choices available and strategies which can be employed at the different stages of development.

[Whitepaper] The Future of Life Sciences Events Management

Explore a new model for events management, and learn how to deliver more value.

[Whitepaper] Leveraging Scientific Insights for Better Healthcare Engagement

To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights.

[Whitepaper] MSL Outlook: What is the Future of Field Medical Affairs?

Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams.

[Whitepaper] Risk-based Approach to Change Management of GxP Systems

Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems.

[Whitepaper] Regulatory Transformation at UCB

UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off.

[Whitepaper] Five Tracking Spreadsheets it’s Time for Regulatory to Retire

Find out how to eliminate regulatory’s tracking spreadsheets for good.

[Whitepaper] A Simpler Approach to RBM in Clinical Trial Management

Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation.

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

Events

.